Influenza virus-like particles as pandemic vaccines

Current Topics in Microbiology and Immunology

Volumn 333, Issue 1, 2009, Pages 269-289

  Kang, S M ^a   Pushko, P ^b   Bright, R A ^b   Smith, G ^b   Compans, R W ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NOVAVAX INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HEPATITIS B VACCINE; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2A; IMMUNOGLOBULIN G2B; IMMUNOLOGICAL ADJUVANT; INFLUENZA VACCINE; INFLUENZA VIRUS HEMAGGLUTININ; LIVE VACCINE; NEUTRALIZING ANTIBODY; PLACEBO; PROTEIN M2; RECOMBINANT VACCINE; VIRUS SIALIDASE; WART VIRUS VACCINE;

AVIAN INFLUENZA VIRUS; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CLINICAL TRIAL; DRUG EFFICACY; DRUG PURIFICATION; DRUG SAFETY; GENE EXPRESSION SYSTEM; HEPATITIS B; HUMAN; HUMORAL IMMUNITY; IMMUNOGENICITY; IMMUNOSTIMULATION; INFECTION CONTROL; INFLUENZA; INFLUENZA VIRUS; INSECT CELL; MORTALITY; NONHUMAN; PANDEMIC INFLUENZA; PRIORITY JOURNAL; PROTEIN ASSEMBLY; REVIEW; VACCINE PRODUCTION; VERRUCA VULGARIS; VIRUS CHARACTERIZATION; VIRUS INHIBITION; VIRUS LIKE AGENT; VIRUS REPLICATION; VIRUS STRAIN;

ANIMALIA; AVIAN INFLUENZA VIRUS; ORTHOMYXOVIRIDAE;

EID: 77950656840     PISSN: 0070217X     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-3-540-92165-3_14     Document Type: Review

References (78)

1. Ali A, Avalos RT, Ponimaskin E, Nayak DP (2000) Influenza virus assembly: effect of influenza virus glycoproteins on the membrane association of M1 protein. J Virol 74(18):8709-8719
2. Assad S, Francis A (1999) Over a decade of experience with a yeast recombinant hepatitis B vaccine. Vaccine 18(1-2):57-67
3. Baumert TF, Ito S, Wong DT, Liang TJ (1998) Hepatitis C virus structural proteins assemble into virus-like particles in insect cells. J Virol 72(5):3827-3836
4. Bresson JL, Perronne C, Launay O, Gerdil C, Saville M, Wood J, Hoschler K, Zambon MC (2006) Safety and immunogenicity of an inactivated split-virion influenza A/Vietnam/1194/2004 (H5N1) vaccine: phase I randomised trial. Lancet 367(9523):1657-1664
5. Bright RA, Carter DM, Daniluk S, Toapanta FR, Ahmad A, Gavrilov V, Massare M, Pushko P, Mytle N, Rowe T, Smith G, Ross TM (2007) Influenza virus-like particles elicit broader immune responses than whole virion inactivated influenza virus or recombinant hemaggluti-nin. Vaccine 25(19):3871-3878
6. Bright RA, Carter DM, Crevar CJ, Toapanta FR, Steckbeck JD, Cole KS, Kumar NM, Pushko P, Smith G, Tumpey TM, Ross TM (2008) Cross-clade protective immune responses to influenza viruses with H5N1 HA and NA elicited by an influenza virus-like particle. PLoS One 3:e1501
7. Buonaguro L, Tornesello ML, Tagliamonte M, Gallo RC, Wang LX, Kamin-Lewis R, Abdelwahab S, Lewis GK, Buonaguro FM (2006) Baculovirus-derived human immunodeficiency virus type 1 virus-like particles activate dendritic cells and induce ex vivo T-cell responses. J Virol 80(18):9134-9143
8. Buonaguro L, Devito C, Tornesello ML, Schroder U, Wahren B, Hinkula J, Buonaguro FM (2007) DNA-VLP prime-boost intra-nasal immunization induces cellular and humoral anti-HIV-1 systemic and mucosal immunity with cross-clade neutralizing activity. Vaccine 25(32):5968-5977
9. Buranathai C, Amonsin A, Chaisigh A, Theamboonlers A, Pariyothorn N, Poovorawan Y (2007) Surveillance activities and molecular analysis of H5N1 highly pathogenic avian influenza viruses from Thailand, 2004-2005. Avian Dis 51(suppl 1):194-200
10. Chen BJ, Leser GP, Morita E, Lamb RA (2007) Influenza virus hemagglutinin and neuraminidase, but not the matrix protein, are required for assembly and budding of plasmid-derived virus-like particles. J Virol 81(13):7111-7123
11. Crawford J, Wilkinson B, Vosnesensky A, Smith G, Garcia M, Stone H, Perdue ML (1999) Baculovirus-derived hemagglutinin vaccines protect against lethal influenza infections by avian H5 and H7 subtypes. Vaccine 17(18):2265-2274
12. Da Silva DM, Velders MP, Nieland JD, Schiller JT, Nickoloff BJ, Kast WM (2001) Physical interaction of human papillomavirus virus-like particles with immune cells. Int Immunol 13(5):633-641
13. De Benedictis P, Joannis TM, Lombin LH, Shittu I, Beato MS, Rebonato V, Cattoli G, Capua I (2007) Field and laboratory findings of the first incursion of the Asian H5N1 highly pathogenic avian influenza virus in Africa. Avian Pathol 36(2):115-117
14. De Jong MD, Hien TT (2006) Avian influenza A (H5N1) J Clin Virol 35(1):2-13
15. Deml L, Kratochwil G, Osterrieder N, Knuchel R, Wolf H, Wagner R (1997a) Increased incorporation of chimeric human immunodeficiency virus type 1 gp120 proteins into Pr55gag virus-like particles by an Epstein-Barr virus gp220/350-derived transmembrane domain. Virology 235(1):10-25
16. Deml L, Schirmbeck R, Reimann J, Wolf H, Wagner R (1997b) Recombinant human immunodeficiency Pr55gag virus-like particles presenting chimeric envelope glycoproteins induce cytotoxic T-cells and neutralizing antibodies. Virology 235(1):26-39
17. Dokland T, Ng ML (2006) Electron microscopy of biology samples. In: Dokland T, Hutmacher DW, Ng ML, Schantz JP (eds) Techniques in microscopy for biomedical application. World Scientific Press, Singapore
18. Fiers W, Neirynck S, Deroo T, Saelens X, Jou WM (2001) Soluble recombinant influenza vaccines. Philos Trans R Soc Lond B Biol Sci 356(1416):1961-1963
19. Galarza JM, Latham T, Cupo A (2005) Virus-like particle (VLP) vaccine conferred complete protection against a lethal influenza virus challenge. Viral Immunol 18(1):244-251
20. Gheysen D, Jacobs E, De Foresta F, Thiriart C, Francotte M, Thines D, De Wilde M (1989) Assembly and release of HIV-1 precursor Pr55gag virus-like particles from recombinant bac-ulovirus-infected insect cells. Cell 59(1):103-112
21. Gomez-Puertas P, Mena I, Castillo M, Vivo A, Perez-Pastrana E, Portela A (1999) Efficient formation of influenza virus-like particles: dependence on the expression levels of viral proteins. J Gen Virol 80(Pt 7):1635-1645
22. Gomez-Puertas P, Albo C, Perez-Pastrana E, Vivo A, Portela A (2000) Influenza virus matrix protein is the major driving force in virus budding. J Virol 74(24):11538-11547
23. Guo L, Lu X, Kang SM, Chen C, Compans RW, Yao Q (2003) Enhancement of mucosal immune responses by chimeric influenza HA/SHIV virus-like particles. Virology 313(2):502-513
24. Harro CD, Pang YY, Roden RB, Hildesheim A, Wang Z, Reynolds MJ, Mast TC, Robinson R, Murphy BR, Karron RA, Dillner J, Schiller JT, Lowy DR (2001) Safety and immunogenicity trial in adult volunteers of a human papillomavirus 16 L1 virus-like particle vaccine. J Natl Cancer Inst 93(4):284-292
25. Horimoto T, Kawaoka Y (1997) Biologic effects of introducing additional basic amino acid residues into the hemagglutinin cleavage site of a virulent avian influenza virus. Virus Res 50(1):35-40
26. Jin H, Leser GP, Zhang J, Lamb RA (1997) Influenza virus hemagglutinin and neuraminidase cytoplasmic tails control particle shape. EMBO J 16(6):1236-1247
27. Kang SM, Compans RW (2003) Enhancement of mucosal immunization with virus-like particles of simian immunodeficiency virus. J Virol 77(6):3615-3623
28. Kawaoka Y, Nestorowicz A, Alexander DJ, Webster RG (1987) Molecular analyses of the hemagglu-tinin genes of H5 influenza viruses: origin of a virulent turkey strain. Virology 158(1):218-227
29. Kirnbauer R, Booy F, Cheng N, Lowy DR, Schiller JT (1992) Papillomavirus L1 major capsid protein self-assembles into virus-like particles that are highly immunogenic. Proc Natl Acad Sci USA 89(24):12180-12184
30. Lanford RE, Luckow V, Kennedy RC, Dreesman GR, Notvall L, Summers MD (1989) Expression and characterization of hepatitis B virus surface antigen polypeptides in insect cells with a baculovirus expression system. J Virol 63(4):1549-1557
31. Latham T, Galarza JM (2001) Formation of wild-type and chimeric influenza virus-like particles following simultaneous expression of only four structural proteins. J Virol 75(13):6154-6165
32. Lenz P, Thompson CD, Day PM, Bacot SM, Lowy DR, Schiller JT (2003) Interaction of papil-lomavirus virus-like particles with human myeloid antigen-presenting cells. Clin Immunol 106(3):231-237
33. Liu C, Eichelberger MC, Compans RW, Air GM (1995) Influenza type A virus neuraminidase does not play a role in viral entry, replication, assembly, or budding. J Virol 69(2):1099-1106
34. Ljubojevic S (2006) The human papillomavirus vaccines. Acta Dermatovenerol Croat 14(3):208
35. Lugovtsev VY, Vodeiko GM, Levandowski RA (2005) Mutational pattern of influenza B viruses adapted to high growth replication in embryonated eggs. Virus Res 109(2):149-157
36. Mahmood K, Bright RA, Mytle N, Carter DM, Crevar CJ, Achenbach JE, Heaton PM, Tumpey TM, Ross TM (2008) H5N1 VLP vaccine induced protection in ferrets against lethal challenge with highly pathogenic H5N1 influenza viruses. Vaccine 26(42):5393-5399
37. Markowitz LE, Dunne EF, Saraiya M, Lawson HW, Chesson H, Unger ER (2007) Quadrivalent human papillomavirus vaccine: Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 56(RR-2):1-24
38. Matassov D, Cupo A, Galarza JM (2007) A novel intranasal virus-like particle (VLP) vaccine designed to protect against the pandemic 1918 influenza A virus (H1N1). Viral Immunol 20(3):441-452
39. Matsuoka Y, Chen H, Cox N, Subbarao K, Beck J, Swayne D (2003) Safety evaluation in chickens of candidate human vaccines against potential pandemic strains of influenza. Avian Dis 47(suppl 3):926-930
40. Moron G, Rueda P, Casal I, Leclerc C (2002) CD8alpha-CD11b+ dendritic cells present exogenous virus-like particles to CD8+ T cells and subsequently express CD8alpha and CD205 molecules. J Exp Med 195(10):1233-1245
41. Moron VG, Rueda P, Sedlik C, Leclerc C (2003) In vivo, dendritic cells can cross-present viruslike particles using an endosome-to-cytosol pathway. J Immunol 171(5):2242-2250
42. Murata K, Lechmann M, Qiao M, Gunji T, Alter HJ, Liang TJ (2003) Immunization with hepatitis C virus-like particles protects mice from recombinant hepatitis C virus-vaccinia infection. Proc Natl Acad Sci USA 100(11):6753-6758
43. Murphy BR, Coelingh K (2002) Principles underlying the development and use of live attenuated cold-adapted influenza A and B virus vaccines. Viral Immunol 15(2):295-323
44. Nayak DP, Hui EK, Barman S (2004) Assembly and budding of influenza virus. Virus Res 106(2):147-165
45. O'Neal CM, Clements JD, Estes MK, Conner ME (1998) Rotavirus 2/6 virus-like particles administered intranasally with cholera toxin, Escherichia coli heat-labile toxin (LT), LT-R192G induce protection from rotavirus challenge. J Virol 72(4):3390-3393
46. Onishchenko GG, Shestopalov AM, Ternovoi VA, Evseenko VA, Durymanov AG, Rassadkin Iu N, Zaikovskaia AV, Zolotykh SI, Iurlov AK, Mikheev VN, Netesov SV, Drozdov IG (2006) Study of highly pathogenic H5N1 influenza virus isolated from sick and dead birds in Western Siberia. Zh Mikrobiol Epidemiol Immunobiol 5:47-54
47. Pattnaik AK, Brown DJ, Nayak DP (1986) Formation of influenza virus particles lacking hemag-glutinin on the viral envelope. J Virol 60(3):994-1001
48. Perdue ML, Garcia M, Senne D, Fraire M (1997) Virulence-associated sequence duplication at the hemagglutinin cleavage site of avian influenza viruses. Virus Res 49(2):173
49. Pushko P, Tumpey TM, Bu F, Knell J, Robinson R, Smith G (2005) Influenza virus-like particles comprised of the HA, NA, M1 proteins of H9N2 influenza virus induce protective immune responses in BALB/c mice. Vaccine 23(50):5751-5759
50. Pushko P, Tumpey TM, Van Hoeven N, Belser JA, Robinson R, Nathan M, Smith G, Wright DC, Bright RA (2007) Evaluation of influenza virus-like particles and Novasome adjuvant as candidate vaccine for avian influenza. Vaccine 25(21):4283-4290
51. Qiao CL, Yu KZ, Jiang YP, Jia YQ, Tian GB, Liu M, Deng GH, Wang XR, Meng QW, Tang XY (2003) Protection of chickens against highly lethal H5N1 and H7N1 avian influenza viruses with a recombinant fowlpox virus co-expressing H5 haemagglutinin and N1 neuraminidase genes. Avian Pathol 32(1):25-32
52. Quan FS, Huang C, Compans RW, Kang SM (2007) Virus-like particle vaccine induces protective immunity against homologous and heterologous strains of influenza virus. J Virol 81(7):3514-3524
53. Quan FS, Steinhauer D, Huang C, Ross TM, Compans RW, Kang SM (2008) A bivalent influenza VLP vaccine confers complete inhibition of virus replication in lungs. Vaccine 26(26):3352-3361
54. Roberts PC, Lamb RA, Compans RW (1998) The M1 and M2 proteins of influenza A virus are important determinants in filamentous particle formation. Virology 240(1):127-137
55. Robertson JS, Nicolson C, Newman R, Major D, Dunleavy U, Wood JM (1992) High growth reas-sortant influenza vaccine viruses: new approaches to their control. Biologicals 20(3):213-220
56. Roldao A, Vieira HL, Charpilienne A, Poncet D, Roy P, Carrondo MJ, Alves PM, Oliveira R (2007) Modeling rotavirus-like particles production in a baculovirus expression vector system: Infection kinetics, baculovirus DNA replication, mRNA synthesis and protein production. J Biotechnol 128(4):875-894
57. Sailaja G, Skountzou I, Quan FS, Compans RW, Kang SM (2007) Human immunodeficiency virus-like particles activate multiple types of immune cells. Virology 362(2):331-241
58. Sasagawa T, Pushko P, Steers G, Gschmeissner SE, Hajibagheri MA, Finch J, Crawford L, Tommasino M (1995) Synthesis and assembly of virus-like particles of human papillomaviruses type 6 and type 16 in fission yeast Schizosaccharomyces pombe. Virology 206(1):126-135
59. Senne DA, Panigrahy B, Kawaoka Y, Pearson JE, Suss J, Lipkind M, Kida H, Webster RG (1996) Survey of the hemagglutinin (HA) cleavage site sequence of H5 and H7 avian influenza viruses: amino acid sequence at the HA cleavage site as a marker of pathogenicity potential. Avian Dis 40(2):425-437
60. Shortridge KF, Zhou NN, Guan Y, Gao P, Ito T, Kawaoka Y, Kodihalli S, Krauss S, Markwell D, Murti KG, Norwood M, Senne D, Sims L, Takada A, Webster RG (1998) Characterization of avian H5N1 influenza viruses from poultry in Hong Kong. Virology 252(2):331-342
61. Skountzou I, Quan FS, Gangadhara S, Ye L, Vzorov A, Selvaraj P, Jacob J, Compans RW, Kang SM (2007) Incorporation of glycosylphosphatidylinositol- anchored granulocyte-macrophage colony-stimulating factor or CD40 ligand enhances immunogenicity of chimeric simian immunodeficiency virus-like particles. J Virol 81(3):1083-1094
62. Smith GE, Fraser MJ, Summers MD (1983) Molecular engineering of the Autographa californica nuclear polyhedrosis virus genome: deletion mutations within the eutralizi gene. J Virol 46(2):584-593
63. Stanley MA (2006) Human papillomavirus vaccines. Rev Med Virol 16(3):139-149
64. Suarez DL, Perdue ML, Cox N, Rowe T, Bender C, Huang J, Swayne De (1998) Comparisons of highly virulent H5N1 influenza A viruses isolated from humans and chickens from Hong Kong. J Virol 72(8):6678-6688
65. Subbarao K, Klimov A, Katz J, Regnery H, Lim W, Hall H, Perdue M, Swayne D, Bender C, Huang J, Hemphill M, Rowe T, Shaw M, Xu X, Fukuda K, Cox N (1998) Characterization of an avian influenza A (H5N1) virus isolated from a child with a fatal respiratory illness. Science 279(5349):393-396
66. Subbarao K, Chen H, Swayne D, Mingay L, Fodor E, Brownlee G, Xu X, Lu X, Katz J, Cox N, Matsuoka Y (2003) Evaluation of a genetically modified reassortant H5N1 influenza A virus vaccine candidate generated by plasmid-based reverse genetics. Virology 305(1):192-200
67. Szecsi J, Boson B, Johnsson P, Dupeyrot-Lacas P, Matrosovich M, Klenk HD, Klatzmann D, Volchkov V, Cosset FL (2006) Induction of eutralizing antibodies by virus-like particles harbouring surface proteins from highly pathogenic H5N1 and H7N1 influenza viruses. Virol J 3:70
68. Takada A, Kuboki N, Okazaki K, Ninomiya A, Tanaka H, Ozaki H, Itamura S, Nishimura H, Enami M, Tashiro M, Shortridge KF, Kida H (1999) Avirulent Avian influenza virus as a vaccine strain against a potential human pandemic. J Virol 73(10):8303-8307
69. Taubenberger JK, Reid AH, Janczewski TA, Fanning TG (2001) Integrating historical, clinical and molecular genetic data in order to explain the origin and virulence of the 1918 Spanish influenza virus. Philos Trans R Soc Lond B Biol Sci 356(1416):1829-1839
70. Triyatni M, Saunier B, Maruvada P, Davis AR, Ulianich L, Heller T, Patel A, Kohn LD, Liang TJ (2002) Interaction of hepatitis C virus-like particles and cells: a model system for studying viral binding and entry. J Virol 76(18):9335-9344
71. Tumpey TM, Garcia-Sastre A, Taubenberger JK, Palese P, Swayne DE, Pantin-Jackwood MJ, Schultz-Cherry S, Solorzano A, Van Rooijen N, Katz JM, Basler CF (2005) Pathogenicity of influenza viruses with genes from the 1918 pandemic virus: functional roles of alveolar macrophages and neutrophils in limiting virus replication and mortality in mice. J Virol 79(23):14933-14944
72. Wang BZ, Liu W, Kang SM, Alam M, Huang C, Ye L, Sun Y, Li Y, Kothe DL, Pushko P, Dokland T, Haynes BF, Smith G, Hahn BH, Compans RW (2007) Incorporation of high levels of chi-meric human immunodeficiency virus envelope glycoproteins into virus-like particles. J Virol 81(20):10869-10878
73. Webby RJ, Perez DR, Coleman JS, Guan Y, Knight JH, Govorkova EA, McClain-Moss LR, Peiris JS, Rehg JE, Tuomanen EI, Webster RG (2004) Responsiveness to a pandemic alert: use of reverse genetics for rapid development of influenza vaccines. Lancet 363(9415):1099-1103
74. Widjaja L, Ilyushina N, Webster RG, Webby RJ (2006) Molecular changes associated with adaptation of human influenza A virus in embryonated chicken eggs. Virology 350(1):137-145
75. Yamshchikov GV, Ritter GD, Vey M, Compans RW (1995) Assembly of SIV virus-like particles containing envelope proteins using a baculovirus expression system. Virology 214(1):50-58
76. Yao Q, Kuhlmann FM, Eller R, Compans RW, Chen C (2000) Production and characterization of simian-human immunodeficiency virus-like particles. AIDS Res Hum Retroviruses 16(3):227-236
77. Ye L, Lin J, Sun Y, Bennouna S, Lo M, Wu Q, Bu Z, Pulendran B, Compans RW, Yang C (2006) Ebola virus-like particles produced in insect cells exhibit dendritic cell stimulating activity and induce neutralizing antibodies. Virology 351(2):260-270
78. Zhang J, Leser GP, Pekosz A, Lamb RA (2000) The cytoplasmic tails of the influenza virus spike glycoproteins are required for normal genome packaging. Virology 269(2):325-234